|
|
|
|
|
1
|
United States Type 2 Diabetes Market |
Nov 2009 |
$7,500.00 |
|
Intellent's new industry report focuses on the US type 2 diabetes market. This report provides valuable insight and access to the competitive information and analysis necessary to make decisions regarding the direction of the market
more...
Published by: Intellent
| Search inside this report |
|
|
2
|
Snapshots US OTC Pharmaceuticals 2009 |
Nov 2009 |
$600.00 |
|
Snapdata's Snapshots US OTC Pharmaceuticals 2009 provides 2008 year-end market size data, with 2009 estimates, 5 years of historical data and five-year forecasts. The Snapshots report gives an instant overview of the US OTC pharmaceutical
more...
Published by: Snapdata International Group
| Search inside this report |
|
|
3
|
Snapshots US Pharmaceuticals 2009 |
Nov 2009 |
$600.00 |
|
Snapdata's Snapshots US Pharmaceuticals 2009 provides 2008 year-end market size data, with 2009 estimates, 5 years of historical data and five-year forecasts. The Snapshots report gives an instant overview of the US pharmaceutical market and
more...
Published by: Snapdata International Group
| Search inside this report |
|
|
4
|
Snapshots US Nasal Products 2009 |
Nov 2009 |
$600.00 |
|
Snapdata's Snapshots US Nasal Products 2009 provides 2008 year-end market size data, with 2009 estimates, 5 years of historical data and five-year forecasts. The Snapshots report gives an instant overview of the US nasal product
more...
Published by: Snapdata International Group
| Search inside this report |
|
|
5
|
Snapshots Denmark OTC Pharmaceuticals 2009 |
Nov 2009 |
$600.00 |
|
Snapdata's Snapshots Denmark OTC Pharmaceuticals 2009 provides 2008 year-end market size data, with 2009 estimates, 5 years of historical data and five-year forecasts. The Snapshots report gives an instant overview of the Danish OTC pharmaceutical
more...
Published by: Snapdata International Group
| Search inside this report |
|
|
6
|
Australia Pharmaceuticals and Healthcare Report Q1 2010 |
Nov 2009 |
$495.00 |
|
Australia’s pharmaceutical market is among the most developed in the Asia-Pacific region. Access tomedication is good across all sections of the population, with per-capita spending calculated at US$352 in2008. While not particularly high by Western
more...
Published by: Business Monitor International
| Search inside this report |
|
|
7
|
Merck & Co. Performance, Products, Pipeline and Potential |
Nov 2009 |
$1,130.00 |
|
Pharmaceutical company intelligence reports from Espicom provide a full review of the company's activities together with five-year sales forecasts for its key products. The company's financial performance is covered in-depth, from its latest results to
more...
Published by: Espicom Healthcare Intelligence
| Search inside this report |
|
|
8
|
Company Financials: Bayer AG |
Nov 2009 |
$75.00 |
|
Introduction The Company Financials offers insights into the financial performance of the company over last five years for about 1000 leading global companies. The datapack covers wealth of financial information relating to income statement, balance sheet,
more...
Published by: Datamonitor
|
|
|
9
|
Takeda Pipeline, Products, Performance, Potential |
Nov 2009 |
$1,130.00 |
|
Pharmaceutical company intelligence reports from Espicom provide a full review of the company's activities together with five-year sales forecasts for its key products. The company's financial performance is covered in-depth, from its latest results to
more...
Published by: Espicom Healthcare Intelligence
| Search inside this report |
|
|
10
|
Nigeria Pharmaceuticals and Healthcare Report Q1 2010 |
Nov 2009 |
$495.00 |
|
The value of Nigeria’s pharmaceutical market in 2008 was NGN80.9bn (US$680mn). We forecast a12.8% year-on-year (y-o-y) growth in local currency during 2009, expecting that the market will grow bya compound annual growth rate (CAGR) of
more...
Published by: Business Monitor International
| Search inside this report |
|
|
11
|
Kenya Pharmaceuticals and Healthcare Report Q1 2010 |
Nov 2009 |
$495.00 |
|
BMI’s proprietary Drug Expenditure Forecast Model reveals that the Kenyan pharmaceutical market willreturn to a double-digit growth rate in 2009 (in local currency terms), after declining to single-digitgrowth the previous year. During 2008, OTC and
more...
Published by: Business Monitor International
| Search inside this report |
|
|
12
|
Argentina Pharmaceuticals and Healthcare Report Q1 2010 |
Nov 2009 |
$495.00 |
|
The value of Argentina’s pharmaceutical market in 2008 was US$3.7bn. BMI’s updated forecasts see themarket reaching a value of US$6.12bn by 2014, representing a compound annual growth rate (CAGR) of12.68% in US dollar terms. With
more...
Published by: Business Monitor International
| Search inside this report |
|
|
13
|
Poland Pharmaceuticals and Healthcare Report Q1 2010 |
Nov 2009 |
$495.00 |
|
Poland is one of the highest value markets in Central and Eastern Europe (CEE) and as a result is adestination for almost all multinationals operating within the region. Poland’s pharmaceutical market hasshown consistently strong growth
more...
Published by: Business Monitor International
| Search inside this report |
|
|
14
|
Thailand Pharmaceuticals and Healthcare Report Q1 2010 |
Nov 2009 |
$495.00 |
|
In BMI’s Pharmaceutical Environment Ratings (BER) table for Q110, Thailand slipped from ninth totenth position among the 15 key markets surveyed in the Asia Pacific region. Thailand’s growing andageing population represents a substantial commercial opportunity
more...
Published by: Business Monitor International
| Search inside this report |
|
|
15
|
Chiropractor Offices |
Nov 2009 |
$129.00 |
|
The US chiropractic industry includes about 36,000 businesses and 60,000 licensed chiropractors with combined annual revenue of nearly $10 billion. No major companies dominate. The industry is highly fragmented: the top 50 chiropractor offices generate
more...
Published by: First Research, Inc.
| Search inside this report |
|
|
16
|
Drug Price/Cost Debate: Coping with Escalating Pricing Pressures |
Nov 2009 |
$2,250.00 |
|
Introduction
Insinuations of profi teering were made against an H1N1 swine flu vaccine manufacturer in the summer of 2009.
As the swine flu epidemic began to take on serious proportions, public scrutiny in the United
more...
Published by: Decision Resources
|
|
|
17
|
Profiting From Consumer Mega-Trends in Asia Pacific: Health |
Nov 2009 |
$1,595.00 |
|
Introduction For three-quarters of Asia Pacific consumers, maintaining or improving health has become more important to them personally over the last two years. This report outlines how over 40 health-driven trends influence
more...
Published by: Datamonitor
|
|
|
18
|
Prostate Cancer Drug Discoveries: What the Future Holds |
Nov 2009 |
$2,460.00 |
|
Prostate cancer is the second leading cause of cancer in the US and the third most common cancer worldwide. More than two million men in the US suffer with prostate cancer. Find out more about
more...
Published by: Espicom Healthcare Intelligence
| Search inside this report |
|
|
19
|
Les Laboratoires Servier: PharmaVitae Profile |
Nov 2009 |
$5,700.00 |
|
Introduction This analysis examines the historical and forecast performance for Servier in the prescription pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts
more...
Published by: Datamonitor
|
|
|
20
|
Functional Drinks in New Zealand |
Nov 2009 |
$250.00 |
|
Datamonitor's Functional Drinks in New Zealand industry profile is an essential resource for top-level data and analysis covering the Functional Drinks industry. It includes detailed data on market size and segmentation, plus textual and graphical
more...
Published by: Datamonitor
| Search inside this report |
|
|
21
|
Functional Drinks in Hong Kong |
Nov 2009 |
$250.00 |
|
Datamonitor's Functional Drinks in Hong Kong industry profile is an essential resource for top-level data and analysis covering the Functional Drinks industry. It includes detailed data on market size and segmentation, plus textual and graphical
more...
Published by: Datamonitor
| Search inside this report |
|
|
22
|
Dealmaking and Industry Outlook: Neurological Disease |
Nov 2009 |
$2,250.00 |
|
The plethora of recent reports of new genes and pathways linked to neurological diseases shows that the underlying
causes of these diseases are far from certain; as a result, therapeutic strategies in effect today may
more...
Published by: Decision Resources
|
|
|
23
|
King Pharmaceuticals Inc.: PharmaVitae Profile |
Nov 2009 |
$5,700.00 |
|
Introduction This analysis examines the historical and forecast performance for King in the prescription pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts
more...
Published by: Datamonitor
|
|
|
24
|
Stakeholder Opinions: Vaccines in Emerging Markets (Asia) - Opportunities in China, India, South Korea and Taiwan |
Nov 2009 |
$3,800.00 |
|
Introduction Over the past decade, vaccines have resurfaced as an attractive commercial proposition for Pharma. The developed world has been the initial focus of vaccine makers due to the better healthcare infrastructure and higher price levels.
more...
Published by: Datamonitor
|
|
|
25
|
Pharmaceutical Manufacturers Report - Indian |
Nov 2009 |
$1,500.00 |
|
The Indian Pharmaceutical Manufacturers Report Plimsoll Publishing Ltd. Do you know.... The top 7 best trading partners in the industry? Which company has the highest sales growth? Which companies have the highest levels of debt? This report is an in-depth financial
more...
Published by: Plimsoll Publishing Ltd.
|
|
|
|
|
|
0 items
